Amicus Therapeutics Inc

Financials

Total assets 886.52 M905.14 M724.17 M777.88 M785.03 M949.87 M Total liabilities 600.14 M597.77 M601.12 M617.71 M590.99 M675.63 M Total equity 286.38 M307.37 M123.05 M160.17 M194.04 M274.24 M Total liabilities & shareholders' equities 886.52 M905.14 M724.17 M777.88 M785.03 M949.87 M Total debt —————— Net debt ——————

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

FOLD

Financials

Amicus Therapeutics Inc

Nouvelles

Davis, EVP de Biomarin Pharmaceutical, vend pour 1,6 million de dollars d’actions

Canaccord raises BioMarin stock price target to $104 on earnings

Celldex Therapeutics Stock Earns 88 RS Rating

BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market

BioMarin T4 2025 : croissance du chiffre d’affaires de 17% malgré les charges ROCTAVIAN

BioMarin posts mixed Q4 results, shares edge lower

Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues

BioMarin earnings loom with estimates falling on Voxzogo worries

BB Biotech 2025 : bénéfice en hausse de 660%, prudence pour 2026

Résultats d’Amicus en vue alors que l’accord BioMarin de 4,8 Md$ attend le vote

Amicus earnings on deck as $4.8B BioMarin deal awaits vote

What to Expect From These Drug/Biotech Players This Earnings Season?